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Abstract
Objective To assess the potential contribution of unmeasured general
health status to patient selection in assessments of the clinical
effectiveness of implantable cardioverter-defibrillator (ICD) therapy.
Design Retrospective cohort study.
Setting Linked data from an ICD registry, heart failure registry, and
Medicare claims data for ICDs implanted in 2005 through 2009.
Participants 29 426 patients admitted to hospital with heart failure aged
66 years or older and eligible for ICD therapy for primary prevention.
Main outcome measures Non-traumatic hip fracture, admission to a
skilled nursing facility, and 30 day mortality—outcomes unlikely to be
improved by ICD therapy.
Results Compared with 17 853 patients without ICD therapy, 11 573
patients with ICD therapy were younger and had lower ejection fraction
and more cardiac admissions to hospital but fewer non-cardiac
admissions to hospital and comorbid conditions. Patients with ICD
therapy had greater freedom from unrelated events after adjusting for
age and sex: hip fracture (hazard ratio 0.77, 95% confidence interval
0.64 to 0.92), skilled nursing facility admission (0.53, 0.50 to 0.55), and
30 day mortality (0.12, 0.10 to 0.15).
Conclusions Lower risks of measured outcomes likely reflect
unmeasured differences in comorbidity and frailty. The findings highlight
potential pitfalls of observational comparative effectiveness research
and support physician consideration of general health status in selecting
patients for ICD therapy.
Introduction
After several landmark clinical trials showed the efficacy of
implantable cardioverter-defibrillator (ICD) therapy,
1 2 the US
Centers for Medicare & Medicaid Services (CMS) expanded
coverage of ICD therapy to include primary prevention of
sudden cardiac death in Medicare beneficiaries with heart
failure.
3Medicarebeneficiariesmostlyconsistofthoseaged65
yearsorolder,inwhomtheriskofsuddencardiacdeathislower
than in the trial patients.
4-6 None the less, one study projected
that ICD therapy may be indicated for as many as 800 000
additional people with heart failure in the United States, most
of whom are 65 years or older.
7
In real world modern clinical practice, patients are selected to
receive ICD therapy on the basis of multiple factors, including
indications and contraindications, underlying disease severity,
comorbid conditions, and overall prognosis. Guideline
recommendationsforbothheartfailureanddevicebasedtherapy
include “anticipated survival of at least a year with good
functional capacity,” which is a crucial but subjective clinical
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RESEARCHassessment. In older patients, cognitive and functional capacity
and social support can influence not only prognosis but also
preferences for a device that prevents sudden cardiac death
withoutimprovementinqualityoflife.Informationaboutthese
factors is often unavailable in large databases, including claims
data, registries, and medical records, which affect the validity
of assessing comparative effectiveness of ICD therapy in real
world patients using these data.
To understand the contribution of unmeasured general health
statustoselectionofpatientsforICDtherapyandpotentialbias
in observational studies using registries and claims data, we
comparedthreeoutcomesamongpatientswithandwithoutICD
therapy that can reflect general health status but are unlikely to
beimprovedbyICDtherapy:hipfracture,admissiontoaskilled
nursing facility, and 30 day mortality.
Methods
Data sources
We conducted a retrospective cohort study of older patients
with heart failure using the CMS ICD registry (2005-08); the
National Cardiovascular Database Registry’s ICD registry
(2005-08); a national clinical registry of patients with heart
failure aggregated from several quality improvement and
accreditation programs, including the American Heart
Association’sGetWiththeGuidelinesprogram(2005-08);and
datafilesonMedicareinstitutionalandnon-institutionalclaims
(2004-09) (see web extra appendix I).
We linked the combined ICD registry and the heart failure
registry to Medicare claims data using four non-unique
identifiers: date of birth, sex, admission date for implantation
of the ICD, and provider ID, which is described in detail
elsewhere.
8 Briefly, we validated this linkage among the subset
of 196 923 patients who had a unique identifier in the ICD
registry. Our linkage using non-unique identifiers yielded 98%
specificity, 95% sensitivity, and 98% positive predictive value
compared with the linkage method using both non-unique and
unique identifiers.
8
Study population, cohorts, and treatment
status
Our study population represented patients with heart failure
who were 66 years or older and eligible for ICD therapy for
primary prevention (see web extra appendix II for detailed
informationonthestudypopulation).Weidentifiedtwocohorts
ofpatientswithandwithoutICDtherapyinthelinkeddatabases
(fig 1⇓). Cohort 1 consisted of the population of Medicare
beneficiaries who were linked to the ICD registry (areas A and
B in fig 1) and the population of Medicare beneficiaries who
were linked to the heart failure registry but not with the ICD
registry (area C). Cohort 2, a smaller but conceptually more
appropriate study population, consisted of Medicare
beneficiaries who were linked to the heart failure registry with
ICD therapy (area B) and without ICD therapy (area C). We
conducted analyses in both cohorts to ensure that the findings
were similar. All study patients had an ejection fraction of 35%
orless.Weexcludedpatientswhohadahistoryofcardiacarrest
or sustained ventricular tachycardia. All patients were eligible
for Medicare for one year before the index procedure or the
index admission to hospital and were 66 years or older. We
excludedpatientswhounderwentbothcardiacresynchronization
therapyandICDtherapy,becausebiventricularpacingimproves
cardiac function and could improve patients’ functional status,
potentially reducing the risk of the outcomes of interest.
Outcomes
We selected three outcomes that are not causally associated
with ICD therapy, are markers for frailty and other unmeasured
pre-existing patient characteristics, and can be accurately
measuredwithhighspecificityinMedicaredata.Theseincluded
admission for non-traumatic hip fracture (that is, fracture not
due to trauma other than a fall and often a consequence of
osteoporosis and a fall), admission to a skilled nursing facility
(a licensed facility that provides short term or long term skilled
care,commonlycalleda“nursinghome”),and30daymortality.
We identified admissions to hospital for non-traumatic hip
fractureonthebasisofadiagnosisofhipfracture(international
classification of diseases, 9th revision, clinical modification
(ICD-9-CM) diagnosis code 820.xx or 733.14) and a related
procedurecode(ICD-9-CMprocedurecode78.55,79.05,79.15,
79.25,79.35,or79.65orcurrentproceduralterminology(CPT)
code 27230-27248).
9 We identified admissions to a skilled
nursingfacilityintheMedicareinstitutionalfiles.Becausesome
such skilled nursing facility admissions identified in Medicare
data are short term and may not be totally related to frailty, we
alsoidentifiedasubsetofnursinghomeadmissionsthatresulted
in stays of more than 20 days (beyond the period for full
Medicare coverage) or death within 20 days as a more accurate
indicator of frailty. We chose mortality within 30 days, a
timeframe during which prophylactic ICD therapy did not
provide a benefit in the landmark clinical trials. For example,
the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
foundthatthemortalitybenefitstartedtoappearapproximately
1.5 years after implantation of an ICD.
1 All patients were
followed until the occurrence of the outcomes and death from
the index date, which was the date of implantation for those
who received ICD therapy and the discharge date from their
admission to hospital for heart failure for those who did not
receive ICD therapy.
Statistical analysis
In patients with or without ICD therapy, we described baseline
characteristics, including use of several preventive care and
screening tests as markers for health seeking behaviors. We
reported counts and person time for each outcome and graphed
cumulative outcome event risks over time using Kaplan-Meier
estimators. We used proportional hazards regression to derive
crude and adjusted hazard ratios comparing patients with and
without ICD therapy.
Somevaluesweremissingforsystolicbloodpressureandserum
levels of sodium, B type natriuretic peptide, and creatinine in
somepatients(seetable1).Wehandledmissingvaluesbyusing
multiple imputation
10 and assuming an underlying multivariate
normal distribution. Our analysis was based on five imputed
datasets where the imputation model included all variables in
the outcome model (ICD use outcomes and potential
confounders) as well as variables related to missingness (see
web extra appendix IV).
11
Sensitivity analyses
We repeated the same analyses after excluding patients older
than 80 years and those with a previous admission to a skilled
nursing facility, because the indication criterion of “expected
survivalwithgoodfunctionalcapacityfor>1year”islesslikely
to be met for these patients.
We used SAS version 9.2 (SAS Institute, Cary, NC) for all
analyses.
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We identified 29 426 patients with heart failure (11 573 with
ICD therapy and 17 853 without ICD therapy) in cohort 1 who
met the eligibility criteria. Patients who received ICD therapy
wereyoungerandmorelikelytobemenandwhitethanpatients
who did not receive ICD therapy. Patients with ICD therapy
also had lower ejection fractions, more previous admissions to
hospitalforcardiacdiseases,morephysicianvisits,andischemic
etiologyofheartfailure(table1⇓).PatientswithoutICDtherapy
had a higher prevalence of non-cardiac admissions to hospital,
previous admissions to a skilled nursing facility, more chronic
kidney or lung disease, metastatic cancer, and other
non-cardiovasculardiseases.Theprevalenceofmanypreventive
procedures and screening tests was higher in patients with ICD
therapy. These findings were similar in cohort 2.
During 42 580 person years of follow-up (mean, 1.4 years) in
cohort1,weobserved676admissionstohospitalforhipfracture
and 9475 admissions to a skilled nursing facility (table 2⇓).
Duringthefirst30days,2428deathsoccurred.Patientswithout
ICD therapy had substantially higher incidence rates of
non-traumatic hip fracture (17 v 9 per 1000 person years),
admissions to a skilled nursing facility (354 v 112 per 1000
personyears),and30daymortality(1699v165per1000person
years).
The cumulative risk of hip fracture at three years was 4.8%
(95%confidenceinterval4.3%to5.3%)amongpatientswithout
ICDtherapyand2.6%(2.3%to3.1%)amongpatientswithICD
therapy.Thecumulativeincidencecurvesdivergedimmediately
after implantation of the ICD (fig 2⇓). The cumulative risk of
admission to a skilled nursing facility at one year was 13.4%
(12.8% to 14.0%) with ICD therapy and 35.7% (34.9% to
36.4%) without ICD therapy. These curves diverged
immediatelyandparalleledwithinafewdaysafterimplantation
of the ICD (fig 2). The pattern was similar for 30 day mortality
(fig 2). The findings were similar in cohort 2 (see web extra
appendix V).
UnadjustedratesofoutcomesinpatientswithICDtherapywere
lower than in patients without ICD therapy for admission for
non-traumatic hip fracture (hazard ratio 0.51, 95% confidence
interval 0.43 to 0.59), admission to a skilled nursing facility
(0.39, 0.37 to 0.41), and 30 day mortality (0.10, 0.09 to 0.12)
(table 3⇓). After adjustment for age and sex, these estimates
moved toward 1. After adjustment for all patient measured
characteristics, these estimates moved further but only
moderatelytoward1andtherisksremainedsubstantiallylower
among patients who received ICD therapy (table 3).
The refined outcome for admission to a skilled nursing facility,
which used a stay of 20 days or longer or death within 20 days,
yielded similar results (tables 2 and 3). After adjustment for all
measuredfactors,therisksremainedsignificantlyloweramong
patients with ICD therapy. Restricting the cohorts to patients
80 years or younger (see web extra appendix VI) or with no
previous admission to a skilled nursing facility (see web extra
appendix VII) did not change the results meaningfully.
Discussion
We compared older patients with and without implantable
converter-defibrillator (ICD) therapy for the risk of three
outcomes that are unlikely to be directly improved by ICD
therapy to assess the impact of unmeasured patient
characteristicsonpatientselectionforICDtherapy.Weobserved
a 50% to 60% lower risk for admission for non-traumatic hip
fracture, admission to a skilled nursing facility, and 30 day
mortality in patients with ICD therapy compared with patients
withheartfailurewithoutICDtherapy.Thesedifferencesinthe
risks of unrelated outcomes were observed immediately after
implantation of the ICD. The differences lessened after
adjustment for measured patient characteristics, but risks
remained lower in patients who received ICD therapy by 16%
to 34%. Given the timing and size of the observed differences,
these results likely reflects baseline differences between the
candidates for ICD therapy and patients who did not receive
ICD therapy that are not measured in Medicare or registry data,
leading to selection bias or “healthy candidate bias.” From a
clinical perspective, these differences reflect appropriate
integration of multiple health dimensions into clinical decision
making in modern clinical practice to select patients who are
most likely to benefit.
The healthy candidate bias that we observed is analogous to
biases described in other fields of epidemiology. Occupational
epidemiologists have long recognized the “healthy worker
survivor effect” when evaluating effects of environmental
exposures. This bias arises in comparisons of workers exposed
to work related toxins and workers not exposed because
relatively healthy people are likely to gain employment and
remainemployed,whereasseverelyillandchronicallydisabled
peopleareordinarilyexcludedfromemployment.
12Similarbias,
known as “healthy user bias” in pharmacoepidemiology, has
been observed among users of preventive medications and
vaccines, such as hormone replacement therapy,
13 14 statins,
15 16
and influenza vaccine.
17 Because implantable devices and
surgical procedures typically pose short term risks in exchange
for long term benefits, patients at high risk of complications or
deemed too sick to benefit are less likely to be selected. In the
Cardiac Arrhythmia Suppression Trial, a similar effect was
observed.
18 This healthy candidate effect is one of the biggest
threats to validity in observational comparative effectiveness
research,especiallyincomparisonsofinvasiveinterventionsto
less invasive alternatives.
Frailtyreflectedbylowfunctionalstatusandimpairedcognitive
function, lack of social support, unrecognized or untreated
depression, and diminished quality of life are associated with
decreased survival in patients with heart failure.
19-23 Each of
these factors may be associated with the decision to offer and
receive ICD therapy. For example, preference for survival was
strongly associated with longer survival in patients with heart
failure in the Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheter Effectiveness.
24 Among patients
who survived fewer than 105 days, 31% indicated that they
would trade more than 90% of their survival days to feel well
for the time remaining, compared with 6% of patients who
survived all 180 days (P<0.005), indicating that those most
likely to die were least likely to have cared about prolonging
survival.
24 In another survey study of 105 consecutive patients
with mean ejection fraction of 21%, 65% of whom received
ICD therapy for primary prevention, recipients of ICD therapy
expressed greater confidence that the device would save their
own lives than those without ICD therapy (P<0.001).
25 These
dataindicatethatrecipientsofICDtherapytendtohaveastrong
preferenceforsurvival,whichislikelytocorrelatedirectlywith
lower rates of death, admission to a skilled nursing facility, and
even hip fracture indirectly. Finally, incomplete depiction of
non-cardiovascular comorbidity is likely another source of
unmeasureddifferencesbetweenpatientswithandwithoutICD
therapy.
25 26
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Eligibility criteria for ICD therapy from both the heart failure
guidelines
26-28 and the device based therapy guidelines
29 28 from
the American College of Cardiology, the American Heart
Association, and the European Society of Cardiology include
anticipatedsurvivalwith“goodfunctionalcapacity”foratleast
one year. We found that 13% of patients with ICD therapy and
36% of patients without ICD therapy were admitted to skilled
nursing facilities within a year if they did not die. Considering
a composite outcome of admission to a skilled nursing facility
anddeath,55%ofpatientswithoutICDtherapywouldnotmeet
the expectation of one year survival with good functional
capacity,whereasasmallerfraction(21%)ofpatientswithICD
therapy would meet the expectation.
A few previous studies have concluded that ICD therapy may
be underused in general or certain Medicare patients without
specific contraindications to implantation of a ICD for primary
prevention of sudden cardiac death.
29-31 While existing
cardiovascularregistriesandMedicaredataincludeinformation
on skilled nursing facilities and ICD-9-CM diagnosis codes for
comorbid conditions, they lack documentation of the severity
of comorbidity, socioeconomic factors, functional status,
cognitivefunction,andqualityoflife.Therefore,apparentgaps
in ICD use assessed using information available in registries
and Medicare data may arise, at least in part, from incomplete
depiction of the appropriateness of patient selection for ICD
therapy.
Our results indicate that a substantial fraction of patients who
were potentially eligible for ICD therapy but did not receive it
may have been at high risk for not “surviving with good quality
of life.” However, our study had limited ability to identify
patients who were specifically at higher risk for admission to a
skilled nursing facility. There are without doubt patients who
didnotreceiveICDtherapywhowouldhavederivedmeaningful
life extension from prevention of sudden death, which are also
not possible to identify in our analyses. Furthermore, some
patients may have declined ICD therapy despite an appropriate
recommendation.
Implications for observational comparative
effectiveness research
Although observational studies provide data on real world
patients in real world settings, they are subject to potential bias
by selection, confounding, survivor bias, and inaccurate
measurement of variables.
31 32 Confounding by indication is
described well in the pharmacoepidemiology literature
32 33and
cancausesignificantbias.However,registriestypicallyinclude
informationonindicationsandcontraindicationsfortreatments.
Therefore, confounding by indication was not a problem in our
study using linked registry and claims data. Healthy candidate
bias, a type of selection or confounding bias, can be the most
challenging bias in observational comparative effectiveness
research for devices and surgeries. We showed the existence of
substantial healthy candidate bias in our ICD example, which
was not controlled by multivariable adjustments for measured
factors and might have affected, at least in part, previous ICD
effectiveness studies.
33-35
Various design-based and statistical approaches have been
suggestedtoovercomehealthyworkersurvivoreffectorhealthy
userbias.Theseincluderestrictiontosurvivors,
35 36laggedtime
or latency analysis,
36 37 g-computation,
37-39 and comparison to
activeusersofsimilarpreventivemedications.
39 40Thetechnique
of restriction to a subset of survivors or to more comparable
groups is a standard approach in epidemiology but one that is
sometimes overlooked or intentionally avoided in favor of a
larger sample size. Other methods, including latency analysis
and g-computation, should be considered and used when
appropriate. Finally, adjustment for proxies for unmeasured
factors by maximizing available information in large databases
using appropriate methods (for example, high dimensional
propensityscoremethods)canpotentiallyachievebettercontrol
for bias in some settings.
40 41
This study suggests two important implications. Firstly, those
responsible for the allocation of scarce healthcare resources in
any country must carefully evaluate whether the efficacy
evidence of expensive technologies such as ICD therapy apply
to their use outside of clinical trials. Secondly, evaluations of
effectiveness from clinical and administrative databases may
overestimatethebenefitofdeviceorsurgicaltherapiesforwhich
selection is influenced by healthy candidate bias.
Several limitations should be considered in interpreting these
findings. Firstly, we identified patients who received and did
notreceiveICDtherapyfromdifferentregistries,whichlimited
our ability to adjust for some factors such as New York Heart
Association functional classification that were only measured
in one of the registries. However, all patients were admitted to
hospital with heart failure, both registries had equally limited
information on non-cardiovascular comorbid conditions, and
neitherregistryincludedinformationonfrailtyorsocialsupport.
Also, all patients were Medicare beneficiaries, which was the
target population of our study, and the findings were replicated
in the secondary cohort (cohort 2) identified in the heart failure
registry. In the comparison of 30 day mortality, it is possible
that there was early excess non-sudden death in the ICD arm,
asreportedaftermyocardialinfarction.
41 42However,thiswould
only have served to diminish the noticeable excess of 30 day
mortality observed among patients who did not receive ICD
therapy. For the non-fatal outcomes, competing risks by death
existinthecurrentstudy.However,ifICDsurvivalbenefitfrom
the trials was translated into this population, our results would
have been underestimates of the true differences in the
occurrence of hip fracture and admissions to a skilled nursing
facility, rendering the selection due to frailty and other
unmeasured factors even larger than observed here.
Conclusion
Difference in survival between patients receiving and not
receiving ICD therapy in this large observational study was
influenced by unmeasured differences in baseline health status,
as indicated by lower risk of non-traumatic hip fracture,
admission to a skilled nursing facility, and 30 day mortality
amongrecipientsofICDtherapy.Ouranalysesofearlymortality
and non-fatal outcomes highlight potential pitfalls of
observational comparative effectiveness analyses of outcomes
associated with one treatment versus another due to healthy
candidate bias. It is not possible to determine from this study
the degree to which apparent underutilization of such therapies
mayinsteadreflectthoughtfulclinicaldecisionsinwhichdoctors
use factors such as frailty to allocate expensive therapies to
patients who are most likely to benefit.
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RESEARCHTables
Table 1| Measured baseline characteristics of patients with or without implantable cardioverter-defibrillator (ICD) therapy. Values are
numbers (percentages) unless stated otherwise
Cohort 2 (heart failure registry population) Cohort 1 (ICD+heart failure registry population)
Characteristics ICD (n=1089) No ICD (n=17 853) ICD (n=11 573) No ICD (n=17 853)
75.1 (5.9) 80.0 (7.8) 75.0 (5.8) 80.0 (7.8) Mean (SD) age (years)
770 (71) 9321 (52) 8514 (74) 9321 (52) Men
888 (82) 15 068 (84) 10 035 (87) 15 068 (84) White race
Previous admissions and outpatient visits:
354 (33) 2844 (16) 2196 (19) 2844 (16) ≥1 heart failure admission
318 (29) 6501 (36) 3290 (28) 6501 (36) ≥1 non-cardiac admission
84 (8) 2679 (15) 663 (6) 2679 (15) ≥1 SNF admission
13.0 (8.7) 10.3 (9.4) 12.7 (8.8) 10.3 (9.4) Mean (SD) outpatient visits
Medical history:
Cancer
177 (16) 3020 (17) 1946 (17) 3020 (17) Any cancer*
17 (2) 566 (3) 161 (1) 566 (3) Metastatic cancer
229 (21) 3860 (22) 2150 (19) 3860 (22) Cerebrovascular disease
407 (37) 8009 (45) 3819 (33) 8009 (45) Chronic kidney disease
523 (48) 8283 (46) 4908 (42) 8283 (46) COPD
83 (8) 3503 (20) 947 (8) 3503 (20) Dementia
142 (13) 2821 (16) 1282 (11) 2821 (16) Depression
584 (54) 8648 (48) 5698 (49) 8648 (48) Diabetes mellitus
26 (2) 527 (3) 246 (2) 527 (3) Dialysis
131 (12) 2755 (15) 1405 (12) 2755 (15) Gastrointestinal ulcer or bleeding
954 (88) 14 165 (79) 10 028 (87) 14 165 (79) Heart failure of ischemic origin
73 (7) 1118 (6) 629 (5) 1118 (6) Liver disease
270 (25) 4147 (23) 2591 (22) 4147 (23) Peripheral vascular disease
Clinical characteristics:
3 (1-4) 3 (1-4) 2 (1-4) 3 (1-4) Median (interquartile range) Charlson
comorbidity score (%)
58.0 (42.8-72.3) 47.1 (32.3-63.5) 58.4 (43.4-73.5) 47.1 (32.3-63.5) Median (interquartile range) eGFR
(mL/min/1.73 m
2)†
25 (20-30) 29 (20-33) 25 (20-30) 29 (20-33) Median (interquartile range) ejection
fraction (%)
842 (346-1560) 1249 (657-2258) 681 (304-1477) 1249 (657-2258) Median (interquartile range) serum BNP
(pg/mL)
786 (72) 12,810 (72) 8989 (78) 12,810 (72) Missing
1.2 (1.0-1.5) 1.3 (1.0-1.8) 1.2 (1.0-1.5) 1.3 (1.0-1.8) Median (interquartile range) serum
creatinine (mg/dL)
14 (1) 11 488 (64) 114 (1) 11 488 (64) Missing
139 (137-141) 138 (136-141) 139 (137-141) 138 (136-141) Median (interquartile range) serum
sodium (mEq/L)
27 (2) 12 032 (67) 157 (1) 12 032 (67) Missing
130 (115-148) 133 (116-152) 131 (118-148) 133 (116-152) Median (interquartile range) systolic
blood pressure (mm Hg)
19 (2) 9230 (52) 196 (2) 9230 (52) Missing
Screening and prevention history:
34 (11) 677 (8) 373 (12) 677 (8) Bone mineral density test‡
82 (8) 1111 (6) 876 (8) 1111 (6) Fecal occult blood test
547 (50) 8423 (47) 6117 (53) 8423 (47) Influenza vaccine
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RESEARCHTable 1 (continued)
Cohort 2 (heart failure registry population) Cohort 1 (ICD+heart failure registry population)
Characteristics ICD (n=1089) No ICD (n=17 853) ICD (n=11 573) No ICD (n=17 853)
86 (27) 1472 (17) 909 (30) 1472 (17) Mammography†
125 (11) 1398 (8) 1076 (9) 1398 (8) Pneumococcal vaccine
262 (34) 2622 (28) 2910 (34) 2622 (28) Prostate specific antigen test§
COPD=chronic obstructive pulmonary disease; eGRF=estimated glomerular filtration rate; SNF=skilled nursing facility; BNP=B type natriuretic peptide.
*Does not include non-melanoma skin cancer.
†eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation
42 after discounting serum creatinine values by 5% to account
for assay variability.
43
‡In women only.
§In men only.
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RESEARCHTable 2| Incidence of admission to a skilled nursing facility (SNF), hospital admission for hip fracture, and 30 day mortality in patients with
or without implantable cardioverter-defibrillator (ICD) therapy
ICD No ICD
Event
Incidence/1000 person years
(95% CI) Events Person years
Incidence/1000 person years
(95% CI) Events Person years
Cohort 1 (ICD and heart failure registry
population):
9 (8 to 10) 209 24 066 17 (16 to 19) 467 26 819 Hip fracture admission
112 (108 to 117) 2438 21 718 354 (346 to 363) 7037 19 852 SNF admission
23 (21 to 25) 556 23 814 78 (74 to 81) 1995 25 662 Death in SNF or length of stay >20 days
165 (141 to 193) 156 945 1699 (1631 to 1770) 2272 1337 30 day mortality
Cohort 2 (heart failure registry
population):
7 (4 to 12) 16 2190 17 (16 to 19) 467 26 819 Hip fracture admission
133 (118 to 150) 258 1934 354 (346 to 363) 7037 19 852 SNF admission
29 (23 to 37) 63 2154 78 (74 to 81) 1995 25 662 Death in SNF or length of stay >20 days
112 (58 to 199) 10 89 1699 (1631 to 1770) 2272 1337 30 day mortality
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RESEARCHTable 3| Hazards of admission to a skilled nursing facility (SNF), hospital admission for hip fracture, and 30 day mortality in patients with
or without an implantable cardioverter-defibrillator (ICD)
Hazard ratio (95% CI)
Event Multivariable adjusted* Age and sex adjusted Unadjusted
Cohort 1 (ICD and heart failure registry
population):
0.84 (0.66 to 1.05) 0.77 (0.64 to 0.92) 0.51 (0.43 to 0.59) Non-traumatic hip fracture
0.71 (0.67 to 0.76) 0.53 (0.50 to 0.55) 0.39 (0.37 to 0.41) SNF admission
0.69 (0.60 to 0.80) 0.50 (0.45 to 0.56) 0.36 (0.33 to 0.39) Death in SNF or length of stay >20 days
0.20 (0.17 to 0.24) 0.12 (0.10 to 0.15) 0.10 (0.09 to 0.12) 30 day mortality
Cohort 2 (heart failure registry population):
0.53 (0.31 to 0.92) 0.63 (0.36 to 1.01) 0.42 (0.23 to 0.67) Non-traumatic hip fracture
0.68 (0.60 to 0.78) 0.60 (0.53 to 0.68) 0.47 (0.41 to 0.53) SNF admission
0.78 (0.53 to 1.15) 0.61 (0.47 to 0.78) 0.45 (0.34 to 0.57) Death in SNF or length of stay >20 days
0.12 (0.06 to 0.22) 0.09 (0.04 to 0.15) 0.07 (0.03 to 0.12) 30 day mortality
*Adjusted for all covariates listed in web extra appendix III, including clinical variables such as ejection fraction, systolic blood pressure, sodium level, serum B
type natriuretic peptide, and estimated glomerular filtration rate.
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RESEARCHFigures
Fig 1 Conceptual relation of data sources and schematic presentation of cohort 1 (implantable converter-defibrillator
(ICD)+heart failure registry population) and cohort 2 (heart failure registry population). Cohort 1 consists of patients receiving
ICD therapy from overlapping area between ICD registry and Medicare data (area A+B) and patients not receiving ICD
therapy from overlapping area between heart failure registry and Medicare data but no overlap with ICD registry (area C).
Cohort 2 consists of patients receiving ICD therapy from overlapping area between the heart failure registry, ICD registry,
and Medicare data (area B) and patients not receiving ICD therapy from area C
Fig 2 Crude survival curves of patients receiving and not receiving implantable converter-defibrillator (ICD) therapy in cohort
1 for admissions for non-traumatic hip fracture, admissions to a skilled nursing home, and 30 day all cause mortality
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